spacer
The Healthcare Sales & Marketing Network celebrates 27 years serving the medical sales & marketing community.Connecting Medical Independent Sales Reps and Distributors with Manufacturers and New Product LinesConnecting Medical Independent Sales Reps and Distributors with Manufacturers and New Product Lines

Searching News Database:  sirolimus-eluting 

 HSMN NewsFeed - 31 May 2023
Excellent 12-Month Results from SELUTION SFA Trial Presented at JET
Devices Interventional
 HSMN NewsFeed - 11 Jan 2023
MedAlliance SELUTION SLR is the first DEB to receive coronary de novo IDE approval, its fourth FDA IDE DEB Approval
Devices Interventional Cardiology FDA
 HSMN NewsFeed - 25 Oct 2022
MedAlliance SELUTION SLR Receives Coronary FDA IDE Approval
Devices Interventional Cardiology FDA
 HSMN NewsFeed - 18 Oct 2022
Cordis Announces Acquisition of MedAlliance, Positioning Itself for Market Leadership in Drug-Eluting Balloon Technology
Devices Drug Delivery Mergers & Acquisitions
 HSMN NewsFeed - 18 Oct 2022
MedAlliance to be Acquired by Cordis
Devices Drug Delivery Mergers & Acquisitions
 HSMN NewsFeed - 8 Oct 2021
18-Month Below-the-Knee Data with MedAlliance's SELUTION SLR(TM) Presented as Late Breaking Trial at VIVA
Devices Interventional
 HSMN NewsFeed - 23 Sep 2020
OrbusNeich(R) Announces China Approval for COMBO(R) Coronary Stent
Devices Interventional Cardiology Regulatory
 HSMN NewsFeed - 13 Jun 2019
Terumo Enhances Coronary Interventional Product Portfolio By Securing Exclusive Global Rights to Orchestra BioMed's Virtue(R) Sirolimus-Eluting Balloon (SEB) through Global Strategic Partnership
Devices Interventional Licensing
 HSMN NewsFeed - 15 Dec 2015
Svelte Medical Systems Announces CE Mark Certification of SLENDER IDS(TM)
Devices Interventional Cardiology Regulatory
 HSMN NewsFeed - 20 May 2014
STENTYS Sirolimus-Eluting Stent Demonstrates Best in Class Efficacy for Heart Attack Patients
Devices Interventional Cardiology
 HSMN NewsFeed - 8 Jan 2014
STENTYS Expands Marketing of its Stents in Asia
Devices Interventional Cardiology Distribution
 HSMN NewsFeed - 30 Oct 2013
REVA Announces Transmission of ReZolve2 Implant and Pilot Trial Update at TCT 2013
Devices Interventional Cardiology
 HSMN NewsFeed - 16 Oct 2012
OrbusNeich's COMBO Dual Therapy Stent(TM) to be Featured in Multiple Clinical Data Presentations Next Week at TCT 2012
Devices Interventional Cardiology
 HSMN NewsFeed - 8 Aug 2012
Cardionovum(R) Expects to Launch Next-Generation Product: Drug-Eluting Coronary Stent System, “PROLIMUS Biograde”
Devices Interventional Cardiology
 HSMN NewsFeed - 15 Jun 2011
SurModics Comments on Johnson & Johnson Announcement
Devices Interventional Cardiology
 HSMN NewsFeed - 15 Jun 2011
Johnson & Johnson Announces Special Charge Related to Restructuring Plans for Cordis Corporation Subsidiary
Devices Interventional Cardiology
 HSMN NewsFeed - 15 Jun 2011
Cordis Announces Discontinuation of NEVO Sirolimus-Eluting Coronary Stent
Devices Interventional Cardiology
 HSMN NewsFeed - 30 Sep 2010
CYPHER(R) Sirolimus Drug-Eluting Stent Remains Unsurpassed in Terms of Clinical Safety and Efficacy
Devices Interventional Cardiology
 HSMN NewsFeed - 2 Sep 2010
Long Term Data Presented at ESC 2010 Further Support the Benefit of The CYPHER(R) Sirolimus Drug-Eluting Stent Compared to The ENDEAVOR(R) Zotarolimus-Eluting Stent in Important High-Risk Subgroups
Devices Interventional Cardiology
 HSMN NewsFeed - 31 Aug 2010
CORDIS Announces Results of Ten-Year CYPHER(R) Sirolimus-Eluting Coronary Stent Follow-Up
Devices Interventional Cardiology
 HSMN NewsFeed - 2 Jun 2010
Apnex Medical, Inc. Names Chas McKhann President, Chief Executive Officer
Devices Neurology Personnel
 HSMN NewsFeed - 25 May 2010
NEVO Sirolimus-eluting Coronary Stent Continues to Demonstrate Excellent Safety and Efficacy Outcomes in New Twelve-Month Data
Devices Interventional Cardiology
 HSMN NewsFeed - 16 Mar 2010
Positive Long Term Data Presented at ACC 2010 Demonstrate Sustained Safety and Efficacy Advantages of the CYPHER(R) Sirolimus Drug-Eluting Stent over the Endeavor(R) Zotarolimus-Eluting Stent
Devices Interventional Cardiology
 HSMN NewsFeed - 31 Aug 2009
First Patient Enrolled in CYPRESS, a Dual Antiplatelet Therapy Trial with the CYPHER(R) Sirolimus-Eluting Coronary Stent
Devices Interventional Cardiology
 HSMN NewsFeed - 19 May 2009
NEVO Sirolimus-Eluting Coronary Stent Yields Superior Results to Taxus Liberte Stent in Pivotal Clinical Trial
Devices Interventional Cardiology
 HSMN NewsFeed - 11 May 2009
Journal of American College of Cardiology Article Reports Fewer Repeat Procedures With Boston Scientific's TAXUS(R) Liberte(R) Stent
Devices Interventional Cardiology
 HSMN NewsFeed - 9 Apr 2009
New Clinical Data at ACC09 Show the CYPHER Sirolimus-eluting Coronary Stent Outperformed TAXUS LIBERTE and ENDEAVOR Stents in Key Outcome Measures
Devices Interventional Cardiology
 HSMN NewsFeed - 26 Mar 2009
Cordis Celebrates 50 Years of Transforming Cardiovascular Care
Devices Interventional Cardiology
 HSMN NewsFeed - 16 Mar 2009
Cordis Corporation Announces Head-to-Head Randomized Clinical Trial Comparing the NEVO Sirolimus-Eluting Coronary Stent to the XIENCE Stent
Devices Interventional Cardiology
 HSMN NewsFeed - 5 Mar 2009
CYPHER Sirolimus-eluting Coronary Stent Demonstrates Sustained Benefits Compared to Bare-Metal Stents in Six-Year Randomized Clinical Trial
Devices Interventional Cardiology
 HSMN NewsFeed - 11 Feb 2009
CYPHER SELECT(R) Plus Sirolimus-eluting Coronary Stent Now Approved in the European Union for Treatment of Patients With Diabetes
Devices Interventional Cardiology Regulatory
 HSMN NewsFeed - 15 Jan 2009
Boston Scientific Announces Court Decision
Devices Interventional Cardiology Litigation
 HSMN NewsFeed - 15 Jan 2009
Court of Appeals Overturns 2005 Patent Verdict Against Cordis
Devices Interventional Cardiology Litigation
 HSMN NewsFeed - 4 Sep 2008
Clinical Data Indicate that Percutaneous Coronary Intervention with the CYPHER(R) Sirolimus-eluting Coronary Stent Is Comparable to Bypass Surgery in Key Safety Measures in Patients with Diabetes and Multi-Vessel Disease
Devices Interventional Cardiology
 HSMN NewsFeed - 1 Sep 2008
Biosensors DES Demonstrates Equivalent Safety and Efficacy to Industry Leading DES in First 'Real World, All Comers' Clinical Study
Devices Interventional Cardiology
 HSMN NewsFeed - 28 Aug 2008
The CYPHER(R) Sirolimus-eluting Coronary Stent Outperforms the Taxus(R) Stent in People with Diabetes According to Clinical Data in the Journal of the American College of Cardiology
Devices Interventional Cardiology
 HSMN NewsFeed - 27 Aug 2008
CYPHER SELECT(R) Plus Sirolimus-eluting Coronary Stent Receives CE Mark Approval for Treatment of Heart Attacks
Devices Interventional Cardiology Regulatory
 HSMN NewsFeed - 30 Jul 2008
Medtronic Starts U.S. Arm of Global Study Comparing Safety of Endeavor(R) and Cypher(R) Drug-Eluting Stents
Devices Interventional Cardiology
 HSMN NewsFeed - 13 May 2008
State-of-the-Art Cobalt Chromium Bare Metal Stent Now Available in Europe
Devices Interventional Cardiology
 HSMN NewsFeed - 5 May 2008
Cardiva Medical, Inc. Completes $15.5 Million Private Equity Financing
Devices Interventional Venture Capital
 HSMN NewsFeed - 31 Mar 2008
Spirit II Results Support Strength of Boston Scientific's Two Drug-Eluting Stent Platforms
Devices Interventional Cardiology
 HSMN NewsFeed - 31 Mar 2008
MIV Preliminary Nine-Month Human Data Affirms Excellent Safety and Efficacy of VESTAsync(TM) Polymer-Free Drug-Eluting Stent
Devices Interventional Cardiology
 HSMN NewsFeed - 30 Mar 2008
Three Year Follow-up Data Suggest Better Outcomes Were Maintained with the CYPHER(R) Sirolimus-Eluting Coronary Stent Compared to Brachytherapy in Patients with In-Stent Reblockage
Devices Interventional Cardiology
 HSMN NewsFeed - 30 Mar 2008
Drug-Eluting Stents Outperform Bare Stents in Heart Attack
Biopharmaceuticals Interventional Cardiology
 HSMN NewsFeed - 29 Mar 2008
Study Results Show Investigational Drug, Prasugrel, Cuts Risk of Stent-Related Clots by More than Half Versus Clopidogrel
Biopharmaceuticals Interventional Cardiology
 HSMN NewsFeed - 11 Feb 2008
Boston Scientific Announces Start of Major European Registry Assessing Different Olimus-Eluting Stents
Devices Interventional Cardiology
 HSMN NewsFeed - 5 Nov 2007
Pooled Analysis of Long-Term Data Suggests Cypher(R) Sirolimus-Eluting Coronary Stent Provides Sustained Clinical Benefits in Patients with Coronary Artery Disease Compared to Bare Metal Stents
 HSMN NewsFeed - 23 Oct 2007
Adoption of Drug-Eluting Stents Associated with Lower Health Care Costs and Improved Clinical Outcomes
Devices Interventional Cardiology
 HSMN NewsFeed - 22 Oct 2007
New Long-Term Data Suggest Clinical Differences in Safety and Efficacy between CYPHER(R) Sirolimus-Eluting Coronary Stent and Taxus Stent
Devices Interventional Cardiology
 HSMN NewsFeed - 22 Oct 2007
MIV Therapeutics Announces Positive Results From First Human Study With Its VESTASYNC Stent
Devices Interventional Cardiology
 HSMN NewsFeed - 21 Oct 2007
New Study Shows Excellent Outcomes for CYPHER(R) Sirolimus-Eluting Coronary Stent in Treatment of Completely Blocked Coronary Arteries
Devices Interventional Cardiology
 HSMN NewsFeed - 17 Oct 2007
Cordis Corporation Announces Clinical Studies and Events at TCT 2007
Devices Interventional Cardiology
 HSMN NewsFeed - 16 Oct 2007
Results of First-In-Man Study With MIVT Low Dose Polymer-Free Drug-Eluting Stent to Be Presented at TCT Conference
Devices Interventional Cardiology
 HSMN NewsFeed - 21 Sep 2007
The CYPHER(R) Sirolimus-Eluting Coronary Stent Outperforms the Taxus Stent in Small Coronary Vessels According to New Clinical Data Analysis Published in the Journal of the American College of Cardiology
Devices Interventional Cardiology
 HSMN NewsFeed - 13 Sep 2007
Largest Study to Date Finds Drug-Eluting Stents and Bare-Metal Stents Yield Similarly Low Mortality Rates
Devices Interventional Cardiology
 HSMN NewsFeed - 5 Sep 2007
Four Analyses of Three-Year Clinical Data Suggest CYPHER(R) Sirolimus-Eluting Coronary Stent May Provide Alternative to Surgery for Patients with Multivessel Disease
Devices Interventional Cardiology
 HSMN NewsFeed - 4 Sep 2007
Largest Study to Date Shows Significant Reductions in Risks of Blood Clots and Reintervention With CYPHER(R) Sirolimus-eluting Coronary Stent Compared to Taxus Stent
Devices Interventional Cardiology
 HSMN NewsFeed - 4 Sep 2007
Two-Year Outcomes From Large Head-to-Head Clinical Trial Indicate Similar Safety Profile in Diabetic Patients for Cypher(R) Sirolimus-Eluting Coronary Stent and Taxus Stent
Devices Interventional Cardiology
 HSMN NewsFeed - 3 Sep 2007
Cypher(R) Sirolimus-Eluting Coronary Stent Demonstrates Sustained Clinical Benefits Compared to Bare Metal Stents in Five-Year Randomized Clinical Trial With No Differences in Long-Term Safety
Devices Interventional Cardiology
 HSMN NewsFeed - 27 Jun 2007
SurModics and Merck Enter Ophthalmic License and Research Collaboration Agreement
Biopharmaceuticals Drug Delivery Licensing
 HSMN NewsFeed - 22 May 2007
CYPHER(R) Sirolimus-Eluting Coronary Stent Had Similar Results to Bypass Surgery and Better Outcomes Than Bare Metal Stents in Subgroup Analysis of Diabetic Patients With Multivessel Coronary Disease
Devices Interventional Cardiology
 HSMN NewsFeed - 21 May 2007
Medtronic Announces Start of 8,800-Patient Clinical Trial Evaluating Drug-Eluting Stent Safety
Devices Interventional Cardiology
 HSMN NewsFeed - 7 May 2007
Conor Medsystems, LLC Reports COSTAR II Pivotal Drug-Eluting Stent Trial Conclusions
Devices Interventional Cardiology
 HSMN NewsFeed - 27 Mar 2007
CYPHER(R) Sirolimus-eluting Coronary Stent Demonstrates Sustained Benefits Compared to Bare-Metal Stents in Five-Year Randomized Clinical Trial
Devices Interventional Cardiology
 HSMN NewsFeed - 26 Mar 2007
Two-Year Patient Registry Results Support Safety and Efficacy of CYPHER(R) Sirolimus-Eluting Coronary Stent in 'Real World' Uses
Devices Interventional Cardiology
 HSMN NewsFeed - 26 Mar 2007
CYPHER(R) Sirolimus-eluting Coronary Stent Had Similar Results to Bypass Surgery in Long-Term Study of Patients With Multi-Vessel Coronary Artery Disease
Devices Interventional Cardiology
 HSMN NewsFeed - 20 Mar 2007
Cordis Corporation to Emphasize Commitment to Interventional Cardiology at ACC.07
Devices Interventional Cardiology
 HSMN NewsFeed - 12 Feb 2007
Multiple Articles in the New England Journal of Medicine Confirm On-Label, Long-Term Safety and Efficacy of the CYPHER(R) Sirolimus-Eluting Coronary Stent Compared to Bare Metal Stents
Devices Interventional Cardiology
 HSMN NewsFeed - 12 Jan 2007
Study in European Heart Journal Favors TAXUS(R) Stent Over Cypher(R) Stent and Bare-Metal Stents in Diabetic Patients
Devices Interventional Cardiology
 HSMN NewsFeed - 16 Nov 2006
Johnson & Johnson Announces Definitive Agreement to Acquire Conor Medsystems, Inc.
Devices Interventional Cardiology Mergers & Acquisitions
 HSMN NewsFeed - 15 Nov 2006
Preliminary Long-Term Clinical Data Show Promising Results for the CYPHER(R) Sirolimus-eluting Coronary Stent in Patients With Multi-Vessel Disease
Devices Interventional Cardiology
 HSMN NewsFeed - 14 Nov 2006
Study Favors TAXUS(R) Stent Over Cypher(R) Stent and Bare-Metal Stents in Diabetic Patients
Devices Interventional Cardiology
 HSMN NewsFeed - 13 Nov 2006
Volcano Announces Clinical Review of Key Presentations From TCT 2006
Devices Interventional Cardiology
 HSMN NewsFeed - 6 Nov 2006
Clinical Studies to be Presented at American Heart Association Scientific Sessions Demonstrate Growing Body of Efficacy and Safety Data for the CYPHER(R) Sirolimus-Eluting Coronary Stent
Devices Interventional Cardiology
 HSMN NewsFeed - 24 Oct 2006
Cordis to Study Impact of Contributing Factors to Stent Thrombosis in Expansion of 30,000-Stent Patient Registry
Devices Interventional Cardiology
 HSMN NewsFeed - 23 Oct 2006
Boston Scientific to Support Landmark STENT Thrombosis Study
Devices Interventional Cardiology
 HSMN NewsFeed - 23 Oct 2006
New Randomized Clinical Trial Results Show the Cypher(R) Sirolimus-Eluting Coronary Stent Outperformed the Taxus Stent in Long Coronary Lesions
Devices Interventional Cardiology
 HSMN NewsFeed - 22 Oct 2006
TAXUS(R) Performance Superior to Cypher(R) in Diabetic Patients in Head-to-Head Study
Devices Interventional Cardiology
 HSMN NewsFeed - 19 Oct 2006
Medtronic Announces Largest Clinical Study Evaluating Drug-Eluting Stent Safety
Devices Interventional Cardiology
 HSMN NewsFeed - 12 Oct 2006
David Kandzari, M.D., International Expert in Interventional Cardiology, Named Chief Medical Officer of Cordis Cardiology
Devices Interventional Cardiology Personnel
 HSMN NewsFeed - 4 Oct 2006
Data Suggest Different Outcomes Between The CYPHER(R) Sirolimus-Eluting Coronary Stent and the Taxus Stent In 'Real World' Settings and Small Vessels
Devices Interventional Cardiology
 HSMN NewsFeed - 13 Sep 2006
Study in New England Journal of Medicine Suggests Heart Attack Patients Fare Better with CYPHER(R) Sirolimus-eluting Coronary Stents Than Bare Metal Stents
Devices Interventional Cardiology
 HSMN NewsFeed - 6 Sep 2006
First Drug-Eluting Stent Approved in Europe for Most Severe Form of Arterial Disease in the Leg
Devices Interventional Regulatory
 HSMN NewsFeed - 6 Sep 2006
Data Suggest the Cypher(R) Sirolimus-Eluting Coronary Stent Provides Sustained Clinical Benefits In Patients With Coronary Artery Disease Compared to Bare Metal Stents
Devices Interventional Cardiology
 HSMN NewsFeed - 22 Jun 2006
Cordis Corporation's Third-Generation Coronary Stent Approved for Use in Europe
Devices Interventional Cardiology Regulatory
 HSMN NewsFeed - 17 May 2006
Cordis Corporation Submits Pre-Market Approval Supplement for Direct Stenting
Devices Interventional Cardiology FDA
 HSMN NewsFeed - 16 May 2006
Study Suggests Drug-Eluting Stent Type and Vessel Size are Important Predictors of Reblockage in Coronary Artery
Devices Interventional Cardiology
 HSMN NewsFeed - 15 May 2006
Patient Registry to Evaluate Long-Term Safety and Efficacy of Cordis Next Generation Drug-Eluting Coronary Stents in Clinical Practice
Devices Interventional Cardiology
 HSMN NewsFeed - 11 May 2006
Cordis Corporation Submits Pre-Market Approval Submission for Reblockage in Coronary Stent
Devices Interventional Cardiology FDA
 HSMN NewsFeed - 9 May 2006
Boston Scientific to Release Latest Clinical Trial Results on Market-Leading TAXUS(R) Coronary Stent Systems at EuroPCR
Devices Interventional Cardiology
Return to NewsFeed  

 Additional items found! 92

Members: click here for search results from The HSMN Archive (password required)
Members Archive contains 92 additional stories matching:
sirolimus-eluting
(Password required)
FindReps - Find Great Medical Independent Sales Reps without recruiter fees.
FindReps - available on the Apple App Store for iPhone and iPad.